Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 326 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells October 15, 2019 ¿Los sobrevivientes del cáncer necesitan ser positivos todo el tiempo? Permitirse... October 12, 2022 September 11, 2001 – Strength is Not Always Unyielding September 11, 2021 Metastatic Breast Cancer Patient Denied Chemotherapy Treatment During COVID-19 Outbreak March 20, 2020 Load more HOT NEWS Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... Why people and culture matter in research Approximately 1 Million of New Maternal Orphans Due to Cancer in...
